MARKET

EDSA

EDSA

Edesa Biotech Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

7.07
+0.26
+3.85%
Opening 13:09 08/13 EDT
OPEN
6.80
PREV CLOSE
6.81
HIGH
7.28
LOW
6.80
VOLUME
96.42K
TURNOVER
--
52 WEEK HIGH
19.10
52 WEEK LOW
1.580
MARKET CAP
62.65M
P/E (TTM)
-9.7630
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average EDSA stock price target is 16.00 with a high estimate of 16.00 and a low estimate of 16.00.

EPS

EDSA News

More
Edesa Biotech Q3 EPS $(0.20) Up From $(0.30) YoY, Sales $110K
Benzinga · 1d ago
PINS, ZN, KNDI and KODK among midday movers
Seeking Alpha · 07/31 16:44
Sonnet BioTherapeutics leads healthcare gainers; ThermoGenesis and Edesa Biotech among losers
Seeking Alpha · 07/31 15:05
TAOP, KODK among premarket losers
Seeking Alpha · 07/31 12:16
Mid-Afternoon Market Update: Nasdaq Turns Higher; Kraton Shares Plummet
Toward the end of trading Thursday, the Dow traded down 0.98% to 26280.13 while the NASDAQ rose 0.37% to 10582.30. The S&P also fell, dropping 0.49% to 3,242.49.
Benzinga · 07/30 18:32
BLNK, PEIX, GTX and BEP among midday movers
Seeking Alpha · 07/30 16:42
Mid-Day Market Update: Crude Oil Down 3%; At Home Group Shares Spike Higher
Midway through trading Thursday, the Dow traded down 1.20% to 26221.54 while the NASDAQ rose 0.01% to 10,543.55. The S&P also fell, dropping 0.76% to 3,233.65.
Benzinga · 07/30 16:17
Healthcare - Top 5 Gainers / Losers
Seeking Alpha · 07/30 15:04

Industry

Biotechnology & Medical Research
+0.82%
Pharmaceuticals & Medical Research
-1.21%

Hot Stocks

Symbol
Price
%Change

About EDSA

Edesa Biotech Inc. is a biopharmaceutical company. The Company is focused on acquiring, developing and commercializing clinical-stage drugs for dermatological and gastrointestinal indications. Its lead product candidate, EB01, is an sPLA2 inhibitor for the topical treatment of chronic allergic contact dermatitis (ACD). Its pipeline also includes EB02 and EB04. EB02, an sPLA2 inhibitor, is being developed as a treatment for patients with hemorrhoids disease (HD). EB04 is being developed for anal fissures. It is also focused on developing biologic drug candidates for therapeutic, prophylactic and diagnostic applications.
More

Webull offers kinds of Edesa Biotech Inc stock information, including NASDAQ:EDSA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EDSA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading EDSA stock methods without spending real money on the virtual paper trading platform.